Extensive experience in highly diverse clinical trials As our clinical trials recruitment table shows (link below), we have significant experience in conducting clinical trials in obesity, especially in collaboration with industry. Sponsors and sponsor staff return to us for extra subject recruitment and for later trials. View/print clinical trials recruitment table* *Requires the free Adobe Acrobat Reader® Below are some of the clinical trials the Weight Management Center has participated in Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. Jul 15 2010;363(3):245-256. Wadden TA, Foreyt JP, Foster GD, et al. Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial. Obesity (Silver Spring). Jun 17 2010. Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). Jan 2009;17(1):30-39. Martin CK, O’Neil PM, Tollefson G, Greenway FL & White MA. The association between food cravings and consumption of specific foods in a laboratory taste test. Appetite, 2008, 51(2), 324-326. Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, Gadde KM, Gupta AK, O’Neil P, Schumacher D, Smith D, Dunayevich E, Tollefson GD, Weber E & Cowley MA. Rational design of a combination medication for the treatment of obesity. Obesity, 2008, 17(1), 130-139. Erondu N, Wadden T, Gantz I, et al. Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity (Silver Spring). Apr 2007;15(4):895-905. Erondu N, Wadden T, Gantz I, Musser B, Nguyen Am, Bays H, Bray G, O’Neil PM, Basdevant A, Kaufman KD, Heymsfield SB, Amatruda JM. Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity, 2007, 15(4), 895-905. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. Feb 15 2006;295(7):761-775. McDuffie JR, Calis KA, Uwaifo GI, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res. Jul 2002;10(7):642-650. Anderson JW, Greenway F, Fujioka K, Gadde KM, McKinney J, O’Neil PM. Bupropion SR enhances weight loss: A 48‑week double-blind, placebo-controlled trial. Obesity Research, 2002, 10, 633–641. McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med. Jul 24 2000;160(14):2185-2191. Anderson JW, Pi‑Sunyer FX, Danforth E, Dujovne CA, Greenway F, Hill JO, Lucas CP, O’Neil PM, Smith DK. Clinical trial design for obesity agents: A workshop report. Obesity Research, 1998, 6(4), 311. | 
